To include your compound in the COVID-19 Resource Center, submit it here.

Shire’s subcutaneous HAE candidate meets in Phase III

Shire plc (LSE:SHP; NASDAQ:SHPG) said SHP616 met the primary endpoint in the Phase III SAHARA trial to treat symptomatic hereditary angioedema in patients ages 12 and older. SHP616 is

Read the full 299 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE